New York is currently home to 4476 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors
Recruiting
CLN-619-001 is a Phase 1, open-label, multi-center study of CLN-619 alone and in combination with pembrolizumab in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Advanced Solid Tumor
CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old
Recruiting
This phase II trial studies how well liposome-encapsulated daunorubicin-cytarabine (CPX-351) works in treating patients with secondary acute myeloid leukemia who are younger than 60 years old. Drugs used in chemotherapy, such as CPX-351, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
01/30/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Recruiting
Spinal muscular atrophy (SMA) is a neurogenetic disorder caused by a loss or mutation in the survival motor neuron 1 gene (SMN1) on chromosome 5q13, which leads to reduced SMN protein levels and a selective dysfunction of motor neurons. SMA is an autosomal recessive, early childhood disease with an incidence of 1:10,000 live births. SMA is the leading cause of infant mortality due to genetic diseases. The purpose of this registry is to assess the long term outcomes of patients with SMA in the c... Read More
Gender:
ALL
Ages:
All
Trial Updated:
01/30/2025
Locations: University of Rochester Medical Center, Rochester, New York
Conditions: Spinal Muscular Atrophy (SMA)
Craniomaxillofacial and Upper Extremity Allotransplantation
Recruiting
The purpose of this study is to evaluate functional and aesthetic outcomes of combined facial and upper extremity composite tissue allografts on patients who have not achieved functional and aesthetic outcomes with conventional reconstructive surgical strategies and prosthetic devices.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
01/30/2025
Locations: NYU Langone Health, New York, New York
Conditions: Face Injuries, Hand Injuries, Craniofacial Injuries, Upper Extremity Injuries, Facial Injuries, Facial Deformity
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
Recruiting
This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival. After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Retroperitoneal Sarcoma, Liposarcoma, Leiomyosarcoma
A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer
Recruiting
This study will test whether valemetostat in combination with atezolizumab is a safe treatment that causes few or mild side effects in people with extensive-stage small cell lung cancer (SCLC). The researchers will test different doses of valemetostat to find the highest dose that causes few or mild side effects in participants. After the dose is found, researchers will test it in a new group of participants to learn more about the safety of the study treatment and see if it is an effective trea... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities), Commack, New York
Conditions: Extensive-stage Small-cell Lung Cancer
Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Recruiting
This is a multicenter, randomized, double-blind, controlled Phase 2/3 trial of zanzalintinib in combination with pembrolizumab versus zanzalintinib-matched placebo in combination with pembrolizumab in subjects with PD-L1 positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) incurable by local therapies who have not received prior systemic therapy for recurrent or metastatic disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Exelixis Clinical Site #3, Shirley, New York
Conditions: Head and Neck Squamous Cell Carcinoma
A Study of OnCARlytics (CF33-CD19) in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumors (OASIS)
Recruiting
This is an open-label, dose escalation and dose expansion, multi-center phase I study evaluating the safety and tolerability of CF33-CD19 administered intravenously (IV) or intratumorally (IT) in combination with blinatumomab in adults with advanced or metastatic solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Solid Tumor, Adult
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)
Recruiting
The main objective of the study is to evaluate the safety, performance and clinical benefits of the Persona implant and its instrumentation in primary total knee arthroplasty
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Syracuse Orthopaedic Specialists, DeWitt, New York
Conditions: Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis
NYC Cancer Outreach Network in Neighborhoods for Equity and Community Translation
Recruiting
NYC CONNECT will carry out a randomized controlled trial (RCT) which will assess the relative effectiveness of two evidence-based strategies to increase cancer screening rates for breast, cervical, and colorectal cancer. The RCT will compare the effectiveness of using a combination of 1) culturally and linguistically tailored cancer education materials and 2) community health workers (CHWs) to provide navigation services for cancer screening (the "patient navigation" \[PN\] arm) versus providing... Read More
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
01/29/2025
Locations: Albert Einstein College of Medicine, Bronx, New York
Conditions: Cancer Screening
PhytoSERM to Prevent Menopause Associated Decline in Brain Metabolism and Cognition
Recruiting
This is a proof-of-concept phase 2 clinical trial to investigate the safety and effect of the phytoestrogenic supplement PhytoSERM on regional brain metabolism by fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) in peri- and postmenopausal women. The investigators hypothesize that there will be a significant difference between the PhytoSERM group and placebo group in glucose brain metabolism.
Gender:
ALL
Ages:
Between 45 years and 60 years
Trial Updated:
01/29/2025
Locations: The Alzheimer's Prevention Program / Weill Cornell Medicine, New York, New York
Conditions: Menopause, Cognitive Change, Brain Disorder, Metabolic
Mechanisms of Resistance to PSMA Radioligand Therapy
Recruiting
This is a multicenter, correlative study to existing Lutetium based prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) trials and uses.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/29/2025
Locations: Memorial Sloan Kettering, New York, New York
Conditions: Prostate Cancer